Savara Inc. (SVRA) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole program is molgramostim, an inhaled biologic in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). The company has no product revenue and has incurred operating losses since inception. This report covers the quarterly period ended September 30, 2024.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(24.2) million | $(16.6) million | $(66.8) million | $(38.6) million |
| Net Loss Per Share | $(0.11) | $(0.10) | $(0.35) | $(0.25) |
| Operating Expenses | $26.4 million | $18.0 million | $72.0 million | $42.4 million |
| Cash & Cash Equivalents | $21.4 million (as of Sept 30, 2024) | |||
| Short-Term Investments | ||||
| Total Liquidity | $219.4 million | |||
| Long-Term Debt | $26.6 million (Principal approx. $26.5M) | |||
| Accumulated Deficit | $460.2 million |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose 46% quarter-over-quarter (Q3 2024 vs. Q3 2023) and 70% year-to-date. This was driven by increased Research and Development (R&D) spending of $6.4 million in Q3 and $23.2 million YTD.
- R&D Drivers: The increase in R&D costs was primarily due to chemistry, manufacturing, and controls (CMC) activities to establish a second drug substance manufacturer ($3.7M in Q3, $12.9M YTD), regulatory affairs, and the ramp-up of the pediatric study.
- Financing Activity: The company raised significant capital in Q3 2024, including an underwritten public offering in July yielding $93.8 million in net proceeds and an "at-the-market" offering in August yielding $24.4 million.
- Interest Income: Other income increased due to higher interest earned on short-term investments resulting from recent equity financings.
Outlook, Risks, and Management Commentary
- Regulatory Timeline: Savara plans to submit a Biological License Application (BLA) to the FDA in the first quarter of 2025 following positive top-line results from its Phase 3 trial.
- Liquidity Position: Management states that current cash and short-term investments ($219.4 million) are sufficient to fund operations for at least the next 12 months. However, additional capital may be required for commercialization.
- Early Access Program: In late September 2024, the company launched an Expanded Access Program (EAP) for molgramostim in select geographies.
- Debt Covenants: The company has a $26.5 million term loan with Silicon Valley Bank. It must maintain cash balances of at least 1.2 times the outstanding principal (or 1.75x in the final year) if cash falls below $40 million. As of September 30, 2024, the company is in compliance.
- Commitments: The company has estimated future obligations of approximately $26.4 million for a second-source API manufacturer and $44.7 million for the IMPALA-2 clinical trial.
Key Facts for Investor Verification
- BLA Submission Date: Verify the timeline for the planned Q1 2025 FDA submission and any potential delays.
- Second Source Manufacturing: Confirm the progress and costs associated with establishing the second drug substance manufacturer, a key driver of recent expense increases.
- Cash Burn Rate: Monitor the monthly cash burn rate to validate the "12-month runway" assertion given the increased operational spend.
- Dilution Risk: Review the impact of the July and August 2024 equity offerings on share count and potential future dilution from outstanding warrants and options.
- Debt Covenant Compliance: Track cash balances relative to the $40 million threshold that triggers stricter liquidity covenants on the term loan.